- Fellowship - Dana-Farber Cancer Institute (2005-2008), Oncology
- Residency - University of California, San Francisco (2002-2005), Internal Medicine
- Medical School - Duke University School of Medicine (1993-2002)
- Graduate School - Duke University School of Medicine (1995-2001)
Kevin Courtney, M.D., Ph.D.
- Internal Medicine - Hematology/Oncology
- Prostate Cancer
- Testicular Cancer
Dr. Courtney is originally from New Hampshire. He initially was drawn to cancer research as an undergraduate at Dartmouth College, where he studied chromium carcinogenesis in the laboratory of Dr. Karen Wetterhahn. He received his M.D. and his Ph.D. in molecular cancer biology from Duke University through the Medical Scientist Training Program. After completing his residency training in Internal Medicine at the University of California, San Francisco, Dr. Courtney returned to the East Coast for his hematology/oncology fellowship at the Dana-Farber Cancer Institute. There he pursued post-doctoral studies in signal transduction in the laboratory of Dr. Lewis Cantley. Following his fellowship, Dr. Courtney continued on as an Instructor in Medicine at Harvard Medical School and an attending oncologist at Dana-Farber in the Lank Center for Genitourinary Oncology. Dr. Courtney joined the faculty at UT Southwestern in 2012. He specializes in genitourinary malignancies, with an emphasis on prostate and kidney cancer. Dr. Courtney's research efforts are focused on developing investigator-initiated clinical trials in prostate and kidney cancer that draw on his background in laboratory research and the outstanding basic science currently being carried out at UTSW. Dr. Courtney enjoys spending time with his family outdoors in the warm Dallas weather.
- American Society of Clinical Oncology (2007-2008), Associate Member
- American Association of Cancer Research (2009), Membership
- Phi Beta Kappa 1992, Membership
- Sigma Xi 1993, Member
- Young Investigator Award 2008, American Society of Clinical Oncology
- Career Development Award 2008, Genentech, Inc. Dana-Farber/Partners Cancer Center
PI3K in Molecular Oncology: Causes of Cancer and Targets for Treatment
Courtney KD, Cantley LC (2012)
- PI3K in Molecular Oncology: Causes of Cancer and Targets for Treatment
The Abl interactor proteins localized to sites of actin polymerization at the tips of lamellipodia and filopodia
Stradal T, Courtney KD, Rottner K, Hahne P, Small JV, Pendergast AM Current Biology 2001 11 891-5
Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway
Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, Pendergast AM Genes and Development 1998 12 1415-24
Localization and phosphorylation of Abl-interactor proteins, Abi-1 and Abi-2, in the developing nervous system
Courtney KD, Grove M, Vandongen H, Vandongen A, LaMantia A-S, Pendergast AM Molecular and Cellular Neuroscience 2000 16 244-57
Optimizing recent advances in metastatic renal cell carcinoma
Courtney KD, Choueiri TK Current Oncology Reports 2009 11 218-226
The PI3K pathway as drug target in human cancer
Courtney KD, Corcoran RB, Engelman JA Journal of Clinical Oncology 2010 28 1075-83
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Courtney KD, Taplin ME Current opinion in oncology 2012 May 24 3 272-7
Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.
Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, Wimberly J, McNeil SS, Kapur P, Lotan Y, Margulis V, Cadeddu JA, Pedrosa I, DeBerardinis RJ, Malloy CR, Bachoo RM, Maher EA Cell metabolism 2018 Aug
A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer.
Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME Clinical genitourinary cancer 2014 Oct
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2a Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Dec JCO2017742627
MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.
Fets L, Driscoll PC, Grimm F, Jain A, Nunes PM, Gounis M, Doglioni G, Papageorgiou G, Ragan TJ, Campos S, Silva Dos Santos M, MacRae JI, O'Reilly N, Wright AJ, Benes CH, Courtney KD, House D, Anastasiou D Nature chemical biology 2018 Nov 14 11 1032-1042
Targeting Renal Cell Carcinoma with a HIF-2 antagonist.
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J Nature 2016 Sep
- The Abl interactor proteins localized to sites of actin polymerization at the tips of lamellipodia and filopodia
- Clinical-translational research in genitourinary oncology
- Industry- and cooperative group-sponsored trials in genitourinary malignancies
- Investigator-initiated clinical trials in kidney cancer
- Novel biomarkers and therapeutics in prostate and kidney cancer
- Investigator-initiated clinical trials in prostate cancer
- Prostate Cancer
- Testicular Cancer
- Kidney Cancer
- Medical Treatment of Genitourinary Cancer
- Bladder Cancer
Showing 1 locations